Syncona Ltd has committed $80 million in new capital to Freeline Therapeutics Ltd which has a candidate gene therapy for haemophilia B in early clinical development. The Series C financing consists of two tranches, of which the first $40 million is being dispensed to support an expansion of manufacturing and clinical development activities, Freeline announced on 19 December.
